Core Insights - Encision Inc. reported a decline in revenue for its 2026 fiscal third quarter, primarily due to the replacement of its surgical procedures by robotic surgeries [1] Financial Performance - The company’s financial results indicate a continued revenue decline, which is attributed to the increasing adoption of surgical robots in the medical field [1] Technology Impact - Encision's patented Active Electrode Monitoring (AEM®) Technology is designed to prevent dangerous radiant energy burns during minimally invasive surgeries, highlighting the importance of its technology in the surgical landscape [1]

Core Insights - Encision Inc. reported financial results for the second quarter of fiscal 2026, ending September 30, 2025, highlighting a total net revenue of $1.52 million [1] - The company experienced a quarterly net loss of $268 thousand, translating to a loss of $(0.02) per diluted share [1] Financial Performance - The quarterly product net revenue was $1.48 million, while service net revenue was $46 thousand, contributing to the total net revenue of $1.52 million [1] - The net loss for the quarter was $268 thousand, indicating challenges in achieving profitability [1]